FDA accepts Biologics License Application for AimovigTM (erenumab)
Amgen announced the FDA has accepted for review the BLA for AimovigTM (erenumab) for prevention of migraine in patients experiencing four or more migraine days per month. If approved, Aimovig is expected to be the first-and-only monoclonal antibody targeting the calcitonin CGRP receptor. July 20, 2017